Clinical trial
NEO-adjuvant Chemo-Immunotherapy in Pancreatic Cancer
NCT06094140 is registered in ClinicalTrials.gov with Australasian Gastro-Intestinal Trials Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- NEO-adjuvant Chemo-Immunotherapy in Pancreatic Cancer
- Lead sponsor
- Australasian Gastro-Intestinal Trials Group
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- May 20, 2022
- Completion date
- June 30, 2026
- Enrollment
- 20 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
pancreatic cancer